Compare Kinross Gold Corporation (KGC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs GeneDx Holdings Corp — how do they compare? Kinross Gold Corporation trades at $23.24 (market cap $26.63B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: Kinross Gold Corporation is far larger — about 14.8× GeneDx Holdings Corp's market cap, and Kinross Gold Corporation pays a 0.64% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| KGC | WGS | |
|---|---|---|
Market Cap | $26.63B | $1.80B |
Sector | Basic Materials | Technology |
52-Week High | $38.06 | $167.51 |
52-Week Low | $15.42 | $34.51 |
Enterprise Value | $25.18B | $1.80B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.65, up 0.35% with strong fundamentals including 35.99% net margin and 35.15% ROE. The stock shows bearish technical signals despite consistent earnings beats and analyst consensus of $37.20 price target. Recent cash flow growth from $259M in 2024 to $1.13B in 2025 supports dividend payments and exploration projects.
KGC presents value opportunity with P/E of 9.6x below industry averages, though technical weakness and gold price volatility pose risks. Production growth to 2.3M+ ounces by 2028 and net cash position provide upside catalysts if gold prices stabilize.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
